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PIEWPOINT
rescribing BiDil
s It Black and White?
usanne B. Haga, PHD, Geoffrey S. Ginsburg, MD, PHD
urham, North Carolina
The approval of BiDil as an adjunct treatment in self-identified blacks with heart failure raises
questions regarding the underlying etiology of drug response in this target population and the
ability to accurately identify patients who are most likely to benefit. Preliminary data have
indicated that differences in nitric oxide synthesis between groups may account for differences
in response to BiDil and genetic studies have begun to elucidate the mechanism of these
differences. Until more accurate selection criteria are developed to identify patients who are
most likely to benefit, both clinicians and the general public will need to consider the unique
issues raised by BiDil. (J Am Coll Cardiol 2006;48:12–4) © 2006 by the American College

































with the push toward personalized medicine, the approval
f a drug that uses race as an identifier to enrich a target
opulation seems counter to the vision for the future of
edicine. In contrast to targeted therapies such as herceptin
r gleevec that use protein or genetic biomarkers to identify
ndividuals likely to benefit from treatment, the approval of
iDil as an adjunct treatment in “self-identified blacks” with
eart failure (HF) continues to rely on the practice of
opulation-based medicine. Although the field of cardiol-
gy has proved more challenging in identifying genomic
arkers predictive of disease, outcome, or drug response,
he use of race may be a step backwards in the area of
argeted therapies. The approval by the U.S. Food and Drug
dministration (FDA) of BiDil occurs at a time when
cientists and the medical community continue to debate
he biological significance of race (1–4) and its use in
edical practice (5,6). The fallout or consequences of these
evelopments are unclear from a scientific, clinical, and
ocial perspective.
Among the questions raised by this approval are whether
ace is a surrogate for underlying biology that explains the
enefit in some blacks, and secondly whether physicians can
ruly identify patients who are most likely to benefit from
he drug using race as the selection criterion. BiDil is a
xed-dose combination of isosorbide dinitrate and hydral-
zine hydrochloride (20 mg/37.5 mg). Initial studies
howed the efficacy of the combination treatment when
ompared with placebo and another vasodilator (prazosin)
7) and with enalapril (8) in men (both black and white)
eceiving digoxin and diuretic therapy for HF. Application
or FDA approval based on these data for the combination
reatment for the general population was rejected.
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ested an improvement in mortality in black patients on
ombination treatment, whereas white patients showed no
enefit over placebo or showed greater benefit from enala-
ril compared to the combination treatment (9). After
onsideration of these data, the FDA indicated that a
ersuasive clinical study limited to black HF patients could
erve as the basis for approval of BiDil. This third study, the
-HeFT (African-American Heart Failure Trial), was de-
igned to confirm the response of combination treatment
dded to standard therapy in black HF patients (10). The
rial was terminated early owing to the statistically lower
ortality rate in patients receiving the isosorbide dinitrate/
ydralazine combination compared with placebo (11).
Race is presumed to be a surrogate for the true basis of
hese observations. Disparate observations in drug response
etween black and white populations with HF may be due
n part to biological, environmental, and/or sociocultural
actors subsumed under the variable of race. In order to
dentify the variables responsible for efficacy of BiDil in
lacks, factors from each of these categories will need to be
haracterized in patients who do and do not respond to
iDil in different populations.
Differences in gene allele frequency among ethnic groups
ave been known for decades. In genes implicated in heart
isease, for example, frequencies of gene variants in para-
xonase 1 (12), angiotensin-converting enzyme (13), and
he adenosine triphosphate-binding cassette reporter 1 (14)
ave been found to differ significantly between blacks and
hites. Given that BiDil works by enhancing production
nd stability of nitric oxide, it has been hypothesized that
educed nitric oxide bioactivity seen in blacks may account
or the improved response to BiDil (15,16). The frequency
f several genetic variants in the endothelial nitric oxide
ynthase gene have been shown to vary between black and
hite populations, however, the clinical significance of this
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July 4, 2006:12–4 Prescribing BiDileen found to be significantly associated with measures of
ower arterial wall stiffness in blacks (18). However, the
ntronic 4a variant was found to be highest in both black and
hite patients with multivessel disease evaluated from a
roup of 194 patients undergoing coronary angiography
lthough no correlation was detected between the variant
nd endothelial function (19). A recent presentation at the
merican Heart Association’s annual meeting showed data
emonstrating an association between the G894T variant
nd BiDil response (20). Validation of this data may provide
dditional criterion for predicting drug efficacy.
Although the consideration of race in the decision to
rescribe certain medications is not new, BiDil is the first
rug specifically targeted to a single population based on a
linical trial composed solely of members of that population.
iven that BiDil is indicated as an adjunct treatment in
self-identified blacks” with HF, how should clinicians decide
ho is to be prescribed BiDil? In the U.S., “black” is often
sed synonymously with African American. In contrast, in
he United Kingdom, black may indicate Black Caribbean,
lack African, or individuals from the Indian subcontinent.
n addition, previous work has demonstrated a range of
ixed ancestry in African Americans, Hispanics, and Mex-
cans (21). In the 2000 U.S. census, more than six million
mericans reported two or more races. The use of self-
dentification is problematic, because it has not always been
hown to be a consistent and reliable measure (22). In the
970s, the U.S. Bureau of the Census examined the reli-
bility of self-reporting by interviewing a sample of house-
old members twice over two years (23). Between the two
nterviews, the ethnic identities changed in more than 34%
f the household members. In addition, the context in
hich the self-identification is made may influence an
ndividual’s decision, resulting in variable responses depend-
ng on who is asking the question and how the information
ight be used (24). Although self-identified race has been
hown to correspond highly with genetic clustering (25), the
ercent of genetic ancestry varies widely (26). These ambi-
uities highlight the need for more precise measurements to
dentify those who will benefit from BiDil.
The social implications of targeting BiDil to a single
acial group may validate and/or increase race-based medical
ractices and create divisions of “white” and “black” drugs in
he public’s mind-set. Since the limitations of the dataset
rom the BiDil studies may not be obvious to the general
ublic or health professionals, enhanced communication is
eeded about the safety and efficacy of the drug in black and
ther populations. By far, the case of BiDil does not resolve
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
FDA  Food and Drug Administration
HF  heart failurehe debate about the biologic significance of race, but in factrovides an opportunity to further clarify the association of
ace with drug response. As the biologic underpinnings of
isease, drug response, and interaction with environmental
ariables continue to be studied, clinicians will need to
onsider the unique challenges raised by BiDil and recog-
ize the limitations of current knowledge. We look forward
o the day when the data are available to support the use of
particular molecular genotype to identify individuals who
re likely to benefit from BiDil.
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